Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206370675> ?p ?o ?g. }
- W3206370675 endingPage "1485" @default.
- W3206370675 startingPage "1485" @default.
- W3206370675 abstract "Smoking cessation medications are routinely used in health care. Research suggests that combining varenicline with the nicotine patch, extending the duration of varenicline treatment, or both, may increase cessation effectiveness.To compare combinations of varenicline plus the nicotine or placebo patch vs combinations used for either 12 weeks (standard duration) or 24 weeks (extended duration).Double-blind, 2 × 2 factorial randomized clinical trial conducted from November 11, 2017, to July 9, 2020, at 1 research clinic in Madison, Wisconsin, and at 1 clinic in Milwaukee, Wisconsin. Of the 5836 adults asked to participate in the study, 1251 who smoked 5 cigarettes/d or more were randomized.All participants received cessation counseling and were randomized to 1 of 4 medication groups: varenicline monotherapy for 12 weeks (n = 315), varenicline plus nicotine patch for 12 weeks (n = 314), varenicline monotherapy for 24 weeks (n = 311), or varenicline plus nicotine patch for 24 weeks (n = 311).The primary outcome was carbon monoxide-confirmed self-reported 7-day point prevalence abstinence at 52 weeks.Among 1251 patients who were randomized (mean [SD] age, 49.1 [11.9] years; 675 [54.0%] women), 751 (60.0%) completed treatment and 881 (70.4%) provided final follow-up. For the primary outcome, there was no significant interaction between the 2 treatment factors of medication type and medication duration (odds ratio [OR], 1.03 [95% CI, 0.91 to 1.17]; P = .66). For patients randomized to 24-week vs 12-week treatment duration, the primary outcome occurred in 24.8% (154/622) vs 24.3% (153/629), respectively (risk difference, -0.4% [95% CI, -5.2% to 4.3%]; OR, 1.01 [95% CI, 0.89 to 1.15]). For patients randomized to varenicline combination therapy vs varenicline monotherapy, the primary outcome occurred in 24.3% (152/625) vs 24.8% (155/626), respectively (risk difference, 0.4% [95% CI, -4.3% to 5.2%]; OR, 0.99 [95% CI, 0.87 to 1.12]). Nausea occurrence ranged from 24.0% to 30.9% and insomnia occurrence ranged from 24.4% to 30.5% across the 4 groups.Among adults smoking 5 cigarettes/d or more, there were no significant differences in 7-day point prevalence abstinence at 52 weeks among those treated with combined varenicline plus nicotine patch therapy vs varenicline monotherapy, or among those treated for 24 weeks vs 12 weeks. These findings do not support the use of combined therapy or of extended treatment duration.ClinicalTrials.gov Identifier: NCT03176784." @default.
- W3206370675 created "2021-10-25" @default.
- W3206370675 creator A5003658167 @default.
- W3206370675 creator A5050726525 @default.
- W3206370675 creator A5055013057 @default.
- W3206370675 creator A5067361252 @default.
- W3206370675 creator A5067551647 @default.
- W3206370675 creator A5077288526 @default.
- W3206370675 date "2021-10-19" @default.
- W3206370675 modified "2023-09-25" @default.
- W3206370675 title "Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation" @default.
- W3206370675 cites W1570903418 @default.
- W3206370675 cites W1581663723 @default.
- W3206370675 cites W1978524840 @default.
- W3206370675 cites W1993729509 @default.
- W3206370675 cites W2051592959 @default.
- W3206370675 cites W2051618313 @default.
- W3206370675 cites W2107200746 @default.
- W3206370675 cites W2123239058 @default.
- W3206370675 cites W2129372385 @default.
- W3206370675 cites W2133053824 @default.
- W3206370675 cites W2135773508 @default.
- W3206370675 cites W2163539177 @default.
- W3206370675 cites W2166328543 @default.
- W3206370675 cites W2180611288 @default.
- W3206370675 cites W2271005668 @default.
- W3206370675 cites W2389469497 @default.
- W3206370675 cites W2735405079 @default.
- W3206370675 cites W2903131156 @default.
- W3206370675 cites W2939123026 @default.
- W3206370675 cites W2978389675 @default.
- W3206370675 cites W3043122900 @default.
- W3206370675 cites W3124053130 @default.
- W3206370675 cites W3124336661 @default.
- W3206370675 cites W3126088119 @default.
- W3206370675 cites W4235260230 @default.
- W3206370675 cites W4238298862 @default.
- W3206370675 doi "https://doi.org/10.1001/jama.2021.15333" @default.
- W3206370675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8527361" @default.
- W3206370675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34665204" @default.
- W3206370675 hasPublicationYear "2021" @default.
- W3206370675 type Work @default.
- W3206370675 sameAs 3206370675 @default.
- W3206370675 citedByCount "24" @default.
- W3206370675 countsByYear W32063706752022 @default.
- W3206370675 countsByYear W32063706752023 @default.
- W3206370675 crossrefType "journal-article" @default.
- W3206370675 hasAuthorship W3206370675A5003658167 @default.
- W3206370675 hasAuthorship W3206370675A5050726525 @default.
- W3206370675 hasAuthorship W3206370675A5055013057 @default.
- W3206370675 hasAuthorship W3206370675A5067361252 @default.
- W3206370675 hasAuthorship W3206370675A5067551647 @default.
- W3206370675 hasAuthorship W3206370675A5077288526 @default.
- W3206370675 hasBestOaLocation W32063706751 @default.
- W3206370675 hasConcept C118552586 @default.
- W3206370675 hasConcept C126322002 @default.
- W3206370675 hasConcept C142724271 @default.
- W3206370675 hasConcept C168563851 @default.
- W3206370675 hasConcept C204787440 @default.
- W3206370675 hasConcept C27081682 @default.
- W3206370675 hasConcept C2776087441 @default.
- W3206370675 hasConcept C2777053506 @default.
- W3206370675 hasConcept C2777843972 @default.
- W3206370675 hasConcept C2779547902 @default.
- W3206370675 hasConcept C2780478649 @default.
- W3206370675 hasConcept C2780687700 @default.
- W3206370675 hasConcept C42219234 @default.
- W3206370675 hasConcept C71924100 @default.
- W3206370675 hasConceptScore W3206370675C118552586 @default.
- W3206370675 hasConceptScore W3206370675C126322002 @default.
- W3206370675 hasConceptScore W3206370675C142724271 @default.
- W3206370675 hasConceptScore W3206370675C168563851 @default.
- W3206370675 hasConceptScore W3206370675C204787440 @default.
- W3206370675 hasConceptScore W3206370675C27081682 @default.
- W3206370675 hasConceptScore W3206370675C2776087441 @default.
- W3206370675 hasConceptScore W3206370675C2777053506 @default.
- W3206370675 hasConceptScore W3206370675C2777843972 @default.
- W3206370675 hasConceptScore W3206370675C2779547902 @default.
- W3206370675 hasConceptScore W3206370675C2780478649 @default.
- W3206370675 hasConceptScore W3206370675C2780687700 @default.
- W3206370675 hasConceptScore W3206370675C42219234 @default.
- W3206370675 hasConceptScore W3206370675C71924100 @default.
- W3206370675 hasIssue "15" @default.
- W3206370675 hasLocation W32063706751 @default.
- W3206370675 hasLocation W32063706752 @default.
- W3206370675 hasLocation W32063706753 @default.
- W3206370675 hasOpenAccess W3206370675 @default.
- W3206370675 hasPrimaryLocation W32063706751 @default.
- W3206370675 hasRelatedWork W1978524840 @default.
- W3206370675 hasRelatedWork W2074930033 @default.
- W3206370675 hasRelatedWork W2114631939 @default.
- W3206370675 hasRelatedWork W2123239058 @default.
- W3206370675 hasRelatedWork W2271005668 @default.
- W3206370675 hasRelatedWork W2429327966 @default.
- W3206370675 hasRelatedWork W2885751483 @default.
- W3206370675 hasRelatedWork W3083183227 @default.
- W3206370675 hasRelatedWork W3093363954 @default.
- W3206370675 hasRelatedWork W3206082057 @default.